Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

ISCOM-based vaccines: the second decade.

Megan T Sanders1, Lorena E Brown, Georgia Deliyannis

  • 1Department of Microbiology and Immunology, The University of Melbourne, Australia.

Immunology and Cell Biology
|March 8, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Understanding and controlling pandemic influenza.

Proceedings of the Japan Academy. Series B, Physical and biological sciences·2026
Same author

Historic 1994 influenza vaccine cohorts define breadth of antibody and B cell responses toward future influenza A and B viruses.

Science translational medicine·2026
Same author

ARNAX is an ideal adjuvant for COVID-19 vaccines to enhance antigen-specific CD4<sup>+</sup> and CD8<sup>+</sup> T-cell responses and neutralizing antibody induction.

Journal of virology·2025
Same author

mRNA vaccines encoding membrane-anchored RBDs of SARS-CoV-2 mutants induce strong humoral responses and can overcome immune imprinting.

Molecular therapy. Methods & clinical development·2024
Same author

Bovine tracheal organoids for studying Mycoplasma bovis respiratory infections.

Veterinary microbiology·2024
Same author

Uncovering strain- and age-dependent innate immune responses to SARS-CoV-2 infection in air-liquid-interface cultured nasal epithelia.

iScience·2024
Same journal

Multi-Omics Comes of Age: Immune Profiling of Human Aging.

Immunology and cell biology·2026
Same journal

Mechanisms of Therapeutic Resistance and Recent Advances in Glioblastoma Treatment.

Immunology and cell biology·2026
Same journal

Ancestry Matters in Decoding Immunity.

Immunology and cell biology·2026
Same journal

Improving COVID-19 Vaccine Uptake Among Ethnic Minority Communities in Wales: A Community-Based Approach.

Immunology and cell biology·2026
Same journal

4-1BB Expression and Signaling Regulates MAIT Cell Activation and Effector Functions.

Immunology and cell biology·2026
Same journal

Highlights of 2025: Advances in the T-Cell Regulation of Germinal Center Response.

Immunology and cell biology·2026
See all related articles

Immunostimulating complexes (ISCOMs) are potent antigen delivery systems. Recent evaluations show ISCOM-based vaccines effectively stimulate immune responses in animals, advancing human vaccine development.

Area of Science:

  • Immunology
  • Vaccinology
  • Biotechnology

Background:

  • The immunostimulating complex (ISCOM) is a 40 nm cage-like structure.
  • ISCOMs comprise antigen, cholesterol, phospholipid, and saponin.
  • ISCOMs function as potent antigen delivery systems with immunostimulating activity.

Purpose of the Study:

  • To review the evaluation of ISCOM-based vaccines in animal models over the last decade.
  • To examine the progress in developing human vaccines utilizing ISCOM adjuvant technology.

Main Methods:

  • Literature review of ISCOM-based vaccine studies.
  • Analysis of immune responses (antibody and cellular) in animal models.
  • Assessment of advancements in human ISCOM vaccine development.

Related Experiment Videos

Main Results:

  • ISCOM-based vaccines have demonstrated significant immunostimulating activity.
  • Both antibody and cellular immune responses are effectively promoted by ISCOMs.
  • Progress has been made in translating ISCOM technology for human vaccine applications.

Conclusions:

  • ISCOMs represent a promising platform for vaccine development.
  • ISCOM adjuvant technology has a proven track record in animal models.
  • Further development holds potential for novel human vaccines.